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Colorectal carcinogenesis is a multistep process, and tumour
progression is promoted by a series of genetic changes that involve
activation of oncogenes and inactivation of tumour suppressor
genes (Vogelstein et al, 1988; Kinzler and Vogelstein, 1998). The
prominent role of some tumour suppressor genes such as APC (5q)
and p53 (17p) has been widely recognized. Several other tumour
suppressor genes have been suggested to exist e.g. on chromosome
bands 1p, 8p, 18q and 22q, and inactivation of these genes may
play a role in colorectal carcinogenesis (Vogelstein et al, 1988;
Miyaki et al, 1999).
Previous studies have demonstrated that at least one copy of
chromosome 18q is lost in over 70 percent of sporadic colorectal
cancers (Vogelstein et al, 1988; Ried et al, 1996; Meijer et al,
1998; Korn et al, 1999). Three candidate tumour suppressor genes,
DCC, SMAD4 and SMAD2, map to this region. Loss of expression
of DCC has been reported in advanced colorectal carcinomas, but
mutations in the coding region seem to be rare, and the position of
DCC as a candidate tumour suppressor is still not clear (Fearon et
al, 1990; Kikuchi-Yanoshita et al, 1992; Cho et al, 1994). SMAD4,
originally named as DPC4, is frequently deleted in pancreatic
cancers (Hahn et al, 1996). Loss of the SMAD4 region relatively
rarely occurs in other types of tumours. An important exception is
colorectal cancer, in which there is good evidence for allelic loss 
at this locus (Takagi et al, 1996; Thiagalingham et al, 1996).
Mutations of SMAD4 and SMAD2 genes have been detected in
some colorectal carcinomas, but the frequency of these mutations
is relatively low (Eppert et al, 1996; Takagi et al, 1996;
Thiagalingham et al, 1996; MacGrogan et al, 1997).
Knudson’s hypothesis that two hits are required for the full inac-
tivation of a tumour suppressor gene has been shown to be correct
in many human cancers (Jones and Laird, 1999). Traditionally, it
has been thought that intragenic mutations and loss of chromo-
somal material inactivate tumour suppressor genes. However, the
fact that methylation of CpG islands located in the promoters of
genes can cause transcriptional silencing, has led to the suggestion
that hypermethylation of tumour suppressor gene promoters is 
one of the mechanisms promoting malignant transformation
(Jones and Laird, 1999). The pattern characterized by methylation
in tumour tissue and lack of methylation in normal mucosa is
consistent with the CpG island methylator phenotype (CIMP),
typical for the colorectal cancers displaying microsatellite insta-
bility (MSI) (Toyota et al, 1999). On the other hand, the promoter
hypermethylation in normal mucosa and lack of methylation in
tumour tissue have been reported in sporadic microsatellite stable
(MSS) colorectal cancers (Kuismanen et al, 1999). Recently, the
involvement of SMAD4 in sporadic colorectal neoplasia was
studied by immunohistochemistry (Salovaara et al, submitted) 
and it was shown that SMAD4 expression was considerably
reduced in unselected colorectal carcinomas. This prompted us to
examine whether promoter hypermethylation plays a role in
SMAD4 inactivation.
One candidate region for the SMAD4 promoter was first
reported by Minami et al (1998). They cloned a 1.4-kb fragment of
the SMAD4 5′ -flanking region from phage library by using the first
coding exon’s sequence as a primer. This SMAD4 promoter lacks
typical TATA boxes and CpG island, but contains some TATA-like
structures (TAAAAT) as well as some binding sites for transcrip-
tion factors (Minami et al, 1998). Another candidate sequence for
the SMAD4 promoter has been characterized by Hagiwara et al
(submitted). This region locates upstream from the previously
reported coding exons and it includes a new non-coding exon
(exon 1), CpG island as well as TATAA and CCAAT boxes and
consensus SP1 binding site (GGGCGGG).
The aim of this study was to confirm the low frequency of
SMAD4 mutations in colorectal cancer and to evaluate the role of
promoter region alterations in SMAD4 inactivation.
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Patients and tissue preparations
Over one thousand fresh-frozen colorectal adenocarcinoma speci-
mens were collected in the Department of Medical Genetics,
Haartaman Institute, University of Helsinki between May 1994
and June 1998 (Aaltonen et al, 1998; Salovaara et al, 2000). To
document the proportion of tumour tissue, all specimens had been
examined histologically. Either normal mucosa or blood was used
as a source of normal tissue for DNA extraction. The MSI status of
the tumours had been determined previously (Aaltonen et al, 1998;
Salovaara et al, 2000). Samples included in the present study are
listed in Tables 1 and 2. The proportion of tumour tissue, stage of
cancers (as Dukes’ stages), MSI status and source of normal tissue
DNA are also presented. 24 out of 55 colorectal tumours included
into this study have been previously analysed by immuno-
histochemistry for the presence of SMAD4 protein and the
SMAD4 expression was below detection level in seven of 
them (Salovaara et al, submitted). The antibody used for
immunostaining was monoclonal antibody to SMAD4 (B-8,
Santa Cruz-7966), which has been previously reported to function
well also on paraffin embedded tissue sections (Wilentz et al,
2000).
SMAD4 PROMOTER METHYLATION
The methylation status of the SMAD4 promoter was studied in 26
MSI and 16 MSS colorectal cancers (CRC). The fragment selected
for this analysis was a CG-rich region characterized by Hagiwara
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Table 1 List of samples included into SMAD4 methylation analysis. Tumour stages are shown as Dukes’ stages (A = tumour limited to mucosa and
submucosa; B = tumour penetrating the muscle wall; C = metastases to regional lymph nodes; D = distant metastases). The proportion of tumour tissue is
shown as percentage. Among 42 sample pairs, 26 tumours were previously shown to be MSI (Aaltonen et al, 19981; Salovaara et al, 2000). Either normal
mucosa (NM) or blood (B) was used as a source of normal tissue for DNA extraction. The presence of SMAD4 protein has been previously analysed from 18
out of 42 tumour samples (Salovaara et al, submitted), and 5 of them were SMAD4 negative. An asterisk marks the 9 samples also included into mutation
analysis.
Sample No. Dukes’ stage Tumour % MSS/ (ref) MSI Origin of normal DNA Immunostaining
by Salovaara et al
C104* B 80 MSI1 NM Not included
C144* B 90 MSI1 NM Not included
C145* C 70 MSI1 NM Ca+
C171* B 75 MSI1 B Ca+
C287 A 75 MSI1 B Ca+
C406* C 85 MSI1 NM Not included
C484 D 80 MSI1 NM Ca+
C500 B 75 MSI1 NM Ca+
C521 D 70 MSI1 NM Ca+
C526 C 90 MSS1 NM Not included
C532 B 75 MSI1 NM Ca+
C543 ? 90 MSI1 NM Not included
C549* A 80 MSI1 NM Not included
C567 B 85 MSI1 NM Not included
C568 B 70 MSI1 NM Ca+
C578 B 85 MSI1 NM Ca+
C732 A 60 MSI2 NM Not included
C733 C 90 MSS2 NM Not included
C744 B 70 MSI2 B Ca+
C758 B 85 MSI2 B Not included
C768 C 55 MSI2 NM Not included
C777 B 65 MSI2 NM Not included
C778 C 90 MSI2 NM Not included
C789 A 50 MSI2 NM Not included
C800 B 70 MSI2 NM Not included
C813 B 90 MSS2 NM Not included
C844 B 70 MSI2 NM Not included
C846 B 90 MSS2 NM Not included
C883 B 85 MSI2 B Ca+
C941 B 75 MSI2 NM Not included
C961 B 95 MSS2 BC a –
C962 C 70 MSS2 B Not included
C964 B 75 MSS2 B Not included
C978* C 60 MSS2 BC a –
C982 C 60 MSS2 BC a –
C984* B 60 MSS2 B Ca+
C986 C 55 MSS2 BC a –
C988 C 50 MSS2 BC a –
C989 C 65 MSS2 B Ca+
C1036 C 90 MSS2 NM Not included
C1051* D 55 MSS2 B Not included
C1058 B 85 MSS2 NM Not includedet al (submitted), including the non-coding exon 1 (Figure 1). To
determine whether this region was hypermethylated, a PCR-based
HpaII and MspI restriction enzyme assay was used. This assay is
based on the ability of the HpaII restriction enzyme to distinguish
CpG sites that are methylated versus those that are nonmethylated.
If the restriction sites are methylated, the methylation-sensitive
HpaII can not cleave the DNA while MspI, which is the methyla-
tion-insensitive isoschizomer of HpaII, is capable to cleave. After
digestion with these enzymes, SMAD4 primers flanking the
HpaII/MspI site are used to test the HpaII and MspI treated DNA
for PCR amplification. PCR product should be detected only when
the original target DNA contains methylated HpaII restriction sites.
Both tumour and normal DNA were digested and the reactions
contained either no enzyme, 25 units of HpaII, or 20 units of MspI
for 16 h at 37° C. To analyse cleavage of the SMAD4 promoter
region, 12.5 ng of DNA from each digest was analysed by PCR 
in 25 µ l reactions containing 1× PCR reaction buffer (PE/ABI), 100
µ M of each dNTP (Finnzymes), 1.5 mM of MgCl2, 1 unit of
AmpliTaqGOLD polymerase (PE/ABI), 10% of DMSO and 
0.4 µ M of each primer. Primers were designed (Primer3) to amplify
408 bp fragment of the SMAD4 promoter (Hagiwara et al,
submitted) containing six HpaII/MspI restriction sites (Figure 1) and
the primer sequences were: forward: 5′ -CAAGTTGGCAGCAA-
CAACAC; and reverse: 5′ -ACATGGCGCGGTTACCT. PCR was
performed for one cycle of 95° C for 10 min followed by 40 cycles of
95° C for 30 s, 60° C for 45 s, and 72° C for 45 s, followed by one
cycle of 72° C for 10 min. The resulting PCR products were
analysed by agarose gel electrophoresis (3% agarose gel).
Mutation analysis of SMAD4
SMAD4 mutations were analysed among 15 MSI and seven MSS
tumours from patients with CRC, nine of those being same as in
methylation analysis. These tumours were unselected regarding
Dukes’ stages A and B (4 tumours of stage A, 11 of stage B, 3 of
stage C, and 4 of stage D, see Table 2). SMAD4 was amplified
from genomic DNA by using previously published primers (Roth
et al, 1999; Zhou et al, 1999). The PCR-reactions were carried out
in 50 µ l reaction volume including 100 ng genomic DNA, 1 ×
PCR reaction buffer (Perkin Elmer Applied Biosystems Division),
200 µ M of each dNTP (Finnzymes), 0.8 µ M of each primer, and
2 units of AmpliTaqGOLD polymerase (PE/ABI). The MgCl2
concentration was 1.5 mM in all reactions except for untranslated
fragment, where the magnesium concentration was 2.5 mM. The
following PCR cycles were used for amplification: exons 1, 2, and
11 – 10 min at 95° C, 40 cycles of 45 s at 95° C, 45 s at 57° C, 1 min
at 72° C; for exons 3,5, and 6 – 10 min at 95° C, 40 cycles of 45 s at
95° C, 45 s at 58° C, 1 min at 72° C; for exons 4, 7, 8, 9, and 10 – 10
min at 95° C, 40 cycles of 45 s at 95° C, 45 s at 56° C, 1 min at
72° C; for 5′ -untranslated fragment – 10 min at 95° C, 40 cycles of
1 min at 95° C, 1 min at 56° C, 1 min 30 s at 72° C. Final extension
10 min at 72° C was used for all fragments. After PCR, 5 µ l of the
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Table 2 Tumour samples included into SMAD4 mutation screening. Tumour stages are shown as Dukes’
stages. The proportion of tumour tissue is presented as percentage. Among 22 tumours, 15 were MSI, seven
being MSS. The MSI/MSS status has been reported previously by Aaltonen et al (1998)1 and Salovaara et al
(2000)2. 10 out of 22 tumours have been previously analysed by SMAD immunostaining (Salovaara et al,
submitted)
Sample No. Dukes’ stage Tumour % MSS/ (ref) MSI Immunostaining
by Salovaara et al
C11 B 80 MSI1 Ca–
C18 A 90 MSI1 Ca+
C43 A 70 MSI1 Not included
C54 D 60 MSI1 Not included
C64 A 70 MSI1 Ca+
C104 B 80 MSI1 Not included
C136 B 75 MSI1 Ca+
C144 B 90 MSI1 Ca+
C145 C 70 MSI1 Ca+
C171 B 75 MSI1 Ca+
C204 B 70 MSI1 Not included
C239 B 90 MSI1 Not included
C331 B 90 MSI1 Not included
C406 C 85 MSI1 Not included
C549 A 80 MSI1 Not included
C977 B 65 MSS2 Ca–
C978 C 60 MSS2 Ca–
C983 D 70 MSS2 Not included
C984 B 60 MSS2 Ca+
C1051 D 55 MSS2 Not included
C1083 D 75 MSS2 Not included
C1088 B 75 MSS2 Not included
Figure 1 SMAD4 promoter region studied for methylation. The primers
designed for this analysis are underlined. ccgg indicates all HpaII/MspI
restriction sites in this region. Grey shading depicts the noncoding exon 1PCR product was run in a 3% agarose (NuSieve) gel to verify the
specificity of the PCR reaction. The rest of the PCR product was
purified using QIAquick PCR purification kit (QIAGEN). Direct
sequencing of the PCR products was performed using the ABI
PRISM Dye Terminator or ABI PRISM dRhodamine cycle
sequencing kits (PE/ABI). Cycle sequencing products were elec-
trophoresed on 6% Long Ranger gels (FMC Bioproducts) and
analysed on an Applied Biosystems model 373A or 377 DNA
sequencer (PE/ABI).
Restriction enzyme digestion
To screen for the presence of a base substitution in exon 2 in
control individuals, restriction enzyme digestion was performed.
NsiI (New England BioLabs) digestion was used to detect the G to
A change at codon 118. NsiI cuts the PCR fragment (530 bp),
which contains the base substitution into two fragments (264 bp
and 266 bp by size) whereas the wild-type fragment lacks the
restriction site and is not digested. The PCR was performed as
described above (SMAD4 mutation analysis, exon 2). The diges-
tion was performed in 1 × NEBuffer (New England BioLabs) 
at 37° C overnight. After digestion, the PCR products were
electrophoresed through 3% agarose gel.
RESULTS
SMAD4 promoter methylation
In this study, the methylation status of the SMAD4 promoter was
analysed using HpaII and MspI digestion. Using this assay, we
examined the methylation status for SMAD4 promoter region in a
group of 26 MSI and 16 MSS colorectal tumours (Table 1). The
amplified sequence contained altogether 55 CpG dinucleotides of
which the methylation status for six CCGG sites was possible to
determine by restriction (Figure 1). PCR amplification was not
detected from any of HpaII digested DNA, suggesting that the
SMAD4 promoter is unmethylated in all cases studied. The non-
digested tumour and normal DNA showed amplification in all
samples, demonstrating the efficiency of PCR reaction (Figure 2).
SMAD4 mutation analysis
Twenty-two primary colon cancers were analysed for mutations of
all exons of SMAD4 by genomic sequencing (Table 2). Also part
of the SMAD4 5′ -untranslated region (331 bp fragment down-
stream from the transcription start site) published by Minami et al
(1998) was included in mutation screening. The only change
detected was G to A transition at the third position for codon 118
(exon 2). This silent change was present in one tumour sample
(C11) and also in corresponding normal DNA. We analysed the
frequency of this variant among 84 Finnish cancer free control
individuals by restriction enzyme digestion (NsiI), and the change
was found in one.
DISCUSSION
Loss of heterozygosity (LOH) on chromosome 18 q is frequently
detected during the progression of colorectal carcinomas. This
suggests the presence of a tumour suppressor gene or genes at this
region. Since identification of SMAD4/DPC4, mutation analyses
of this gene have been carried out in many cancer types. However,
a relatively low frequency of mutations (<10%) has been found in
most cancer types; the only exception being pancreatic cancer,
where the mutation frequency is approximately 20% (Hahn et al,
1996; Nagatake et al, 1996; Scutte et al, 1996; Takagi et al, 1996;
Thiagalingham et al, 1996; Rozenblum et al, 1997).
In addition to loss of chromosomal material and intragenic muta-
tions there is a third mechanism, DNA methylation, which may have
important role in inactivation of tumour suppressor genes. Two
types of DNA methylation changes appear to be connected with the
progression of malignant tumours; hypomethylation induced activa-
tion of oncogenes and hypermethylation based silencing of tumour
suppressor genes (Laird and Jaenish, 1994). Main targets of hyper-
methylation are normally unmethylated CpG islands locating in
gene promoter regions. Methylation of cytosine at CpG dinucleo-
tides of 5′ CpG islands has been associated with transcriptional
silencing of tumour suppressor genes in a variety of human cancers
(Jones and Laird, 1999). For example, VHL gene promoter is com-
monly hypermethylated in renal cancers and RBI gene in retino-
blastoma, respectively (Sakai et al, 1991; Herman et al, 1994).
In the present study, we examined whether hypermethylation of
promoter could be an alternative mechanism to coding region
mutations for SMAD4 inactivation. The CpG island near non-
coding exon 1 was selected for this analysis (Figure 1), since it is
well documented that methylation has important regulatory effects
especially when involving these CpG rich areas (Bird, 1986).
Twenty-six MSI and 16 MSS tumour and corresponding normal
DNAs were selected for the analysis and no evidence of hyper-
methylation was found. The region analysed here contains many
promotor associated structures. While we cannot exclude the exis-
tence of other relevant sequences, we consider the region analysed
here as a likely candidate for the SMAD4 promoter. Six CCGG
sites were available for methylation analysis by restriction. The
possibility, that methylation of other CpG sites are important in
silencing the SMAD4 gene cannot be excluded. Bearing these
cautions in mind, our data suggests that the hypermethylation of
the SMAD4 promoter region is not a key mechanism in SMAD4
inactivation.
In a recent study by Zhou et al (1999) two mutations were iden-
tified in the SMAD4 5′ -untranslated region among the 6 endo-
metrial tumours that had previously failed to express wild type
SMAD4 (Zhou et al, 1999). In that study the mutation screening
was focused on a 331 bp long fragment, which spanned
nucleotides –262 to +69 from the transcription start site. This frag-
ment is part of the SMAD4 5′ -untranslated region published by
Minami et al (1998) and it contains several important transcription
factor binding sites (Minami et al, 1998). To examine whether the
region is mutated also in colorectal carcinomas, we sequenced this
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Figure 2 Methylation analysis of CpG islands of SMAD4 promoter in two
colorectal cancer samples (C789, lanes 1–6 and C800, lanes 7–12). Lanes 1,
2, 7 and 8: PCR product from nondigested normal (N) and tumour (T) DNA.
Lanes 3, 4, 9 and 10: lack of PCR product from HpaII digested normal and
tumour DNA. Lanes 5, 6, 11 and 12: lack of PCR product from MspI digested
normal and tumour DNA331-bp fragment from 15 MSS and seven MSI tumour samples
and found no changes.
Miyaki et al (1999) analysed SMAD4 mutations from 176
colorectal tumours and found that SMAD4 mutation frequencies
were 0% in adenoma, 10% in intramucosal carcinoma, 7% in
primary invasive carcinoma without metastasis, 35% in primary
invasive carcinoma with metastasis and 31% in distant metastasis.
Thus, the frequency of SMAD4 mutations was correlating with the
stage of colorectal cancer (Miyaki et al, 1999). Similar results
were also published by Koyama et al (1999). They found somatic
SMAD4 mutation in 7 of 64 (11%) colorectal tumours of clinical
stages II or III, all these tumours also showing LOH at 18q21. In
the present study, 22 primary CRCs were selected into the SMAD4
mutation screening and the only change detected was a polymor-
phism in exon 2 (C11). According to the literature, SMAD4 poly-
morphisms are rare, so the frequency of this variant among Finnish
control individuals was evaluated. In total, 84 controls were
analysed and the change was found in one of them.
Our results suggest that SMAD4 is not frequently mutated in
primary non-metastatic colorectal carcinoma and that the hyper-
methylation of the SMAD4 promoter region is not a key mecha-
nism in colorectal tumorigenesis. As expression of SMAD4
appears to be decreased or lost in most colorectal cancers
(Salovaara et al, submitted), further work is necessary to under-
stand the molecular mechanisms of SMAD4 inactivation.
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